Statement of ethics The study was approved by the West Midlands - Solihull Research Ethics Committee (17/WM/0179) and all subjects provided written informed consent according to the Declaration of Helsinki principles
Pancreatitis is a known risk
Early Use of GLP-1 Therapy: Are We Starting Treatment Too Late in Diabetes Care
Is my airway problem structural or is it going to respond to weight loss
Depending on the drug, it may also lower cardiovascular risk or the likelihood of kidney complications in those with type 2 diabetes, ease heart failure symptoms, reduce liver fat, improve metabolic dysfunction, and lessen the severity of sleep apnea
Because of the way it works, it's only FDA-approved for people with certain genetic conditions, namely: Proopiomelanocortin (POMC) deficiency, Proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, Leptin receptor (LEPR) deficiency, and Bardet-Biedl syndrome (BBS)